Edgestream Partners L.P. Sells 6,573 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Edgestream Partners L.P. cut its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 74.5% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,249 shares of the biopharmaceutical company's stock after selling 6,573 shares during the quarter. Edgestream Partners L.P.'s holdings in Regeneron Pharmaceuticals were worth $1,426,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Pinney & Scofield Inc. bought a new position in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $25,000. E Fund Management Hong Kong Co. Ltd. raised its holdings in Regeneron Pharmaceuticals by 344.4% in the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 31 shares during the period. Tompkins Financial Corp acquired a new stake in Regeneron Pharmaceuticals in the first quarter worth $32,000. Curat Global LLC acquired a new stake in Regeneron Pharmaceuticals in the first quarter worth $32,000. Finally, Crowley Wealth Management Inc. acquired a new stake in Regeneron Pharmaceuticals in the fourth quarter worth $36,000. 83.31% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have weighed in on REGN shares. Morgan Stanley cut their target price on shares of Regeneron Pharmaceuticals from $755.00 to $754.00 and set an "overweight" rating on the stock in a report on Thursday, July 10th. Cantor Fitzgerald started coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 22nd. They set an "overweight" rating and a $695.00 price objective on the stock. Royal Bank Of Canada lowered shares of Regeneron Pharmaceuticals from a "moderate buy" rating to a "hold" rating and set a $662.00 price objective on the stock. in a report on Friday, May 30th. Truist Financial dropped their price objective on shares of Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating on the stock in a report on Wednesday, April 30th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a report on Monday, June 9th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have issued a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $823.54.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN traded down $7.48 during midday trading on Friday, reaching $542.52. The stock had a trading volume of 1,307,803 shares, compared to its average volume of 929,805. The firm has a market cap of $58.57 billion, a PE ratio of 13.81, a P/E/G ratio of 2.01 and a beta of 0.33. The company has a current ratio of 4.93, a quick ratio of 4.03 and a debt-to-equity ratio of 0.09. The firm has a 50 day simple moving average of $544.44 and a 200-day simple moving average of $614.31. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). The company had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 15.27% and a net margin of 31.94%. The business's quarterly revenue was down 3.7% on a year-over-year basis. During the same period in the previous year, the firm posted $9.55 EPS. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.65%. The ex-dividend date of this dividend was Tuesday, May 20th. Regeneron Pharmaceuticals's payout ratio is 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.